Publication: Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis
Issued Date
2020-01-01
Resource Type
ISSN
14710528
14700328
14700328
Other identifier(s)
2-s2.0-85087805039
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
BJOG: An International Journal of Obstetrics and Gynaecology. (2020)
Suggested Citation
R. Wattanayingcharoenchai, S. Rattanasiri, C. Charakorn, J. Attia, A. Thakkinstian Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology. (2020). doi:10.1111/1471-0528.16366 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/58277
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis
Abstract
© 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists Background: The efficacy of hormonal regimens for the prevention of endometrioma recurrence in women who have undergone conservative surgery is still controversial. Objective: To compare the efficacy of different hormonal regimens in this context and to rank them. Search strategy: MEDLINE and Scopus databases were searched through January 2020. Selection criteria: Randomised controlled trials (RCTs) or cohorts, comparing the effect of any pair of interventions (i.e. cyclic oral contraceptives [OC], continuous OC, gonadotropin-releasing hormone agonist [GnRHa], dienogest [DNG], levonorgestrel-releasing intrauterine system [LNG-IUS] and expectant management) on endometrioma recurrence were selected. Data collection and analysis: Data were independently extracted by two reviewers. Relative treatment effects were estimated using network meta-analysis (NMA) and ranked in descending order. Main results: Six RCTs (675 patients) and 16 cohorts (3089 patients) were included. NMA of the RCTs involving expectant management, cyclic OC, continuous OC, GnRHa and GnRHa + LNG-IUS, showed that all hormonal regimens had a nonsignificant lower risk of endometrioma recurrence compared with expectant management. NMA of the cohorts involving expectant, cyclic OC, continuous OC, GnRHa, DNG, LNG-IUS, GnRHa + OC, and GnRHa + LNG-IUS indicated that LNG-IUS, DNG, continuous OC, GnRHa + OC and cyclic OC had a significantly lower risk of endometrioma recurrence than expectant management. LNG-IUS was ranked highest, followed by DNG and GnRHa + LNG-IUS. Long-term use of hormonal treatment either OC or progestin had a significantly lower risk of endometrioma recurrence than expectant treatment. Conclusion: In the NMA of RCTs, there was no evidence supporting hormonal treatment for postoperative prevention of endometrioma recurrence. This was at odds with the cohort evidence, which found the protective effect of OC and progestin regimens, especially long-term treatment. Large-scale RCTs of these agents are still required. Tweetable abstract: Hormonal regimens given as long-term treatment tend to reduce risk of endometrioma recurrence after conservative surgery.